Most importantly, our findings provide a rational basis for future precision therapy trials potentially impacting >30% of primary, advanced and recurrent NPC, for the classes of MAT2A and PRMT5 inhibitors. This evidence concerns the gene PRMT5 and nasopharyngeal carcinoma.